Which Should Be Used First for ALK-Positive Non-Small-Cell Lung Cancer: Chemotherapy or Targeted Therapy? A...

Area of Science:

• Oncology
• Pharmacology
• Clinical Trials

Background:

• Precision medicine utilizes targeted therapies, but optimal sequencing with chemotherapy remains unclear.
• Anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) is a key area for targeted treatment.
• The impact of sequential treatment strategies in ALK-positive NSCLC requires investigation.

Purpose of the Study:

• To evaluate the effect of sequential targeted therapy and chemotherapy in advanced ALK-positive NSCLC.
• To determine if the order of administering ALK inhibitors and chemotherapy influences patient outcomes.

Main Methods:

• A meta-analysis of randomized controlled trials comparing ALK inhibitors with chemotherapy.
• Hazard ratios (HRs) and 95% confidence intervals (CIs) were estimated for progression-free survival (PFS) and overall survival (OS).
• Random effects models and two-sided statistical tests were employed.

Main Results:

• Five studies with 1404 patients were included.
• ALK targeted therapy significantly improved PFS compared to chemotherapy (HR = 0.48; 95% CI, 0.42⁻0.55).
• No significant difference in overall survival (OS) was observed between the groups (HR = 0.88; 95% CI, 0.72⁻1.07).
• Sensitivity analyses confirmed improved PFS but not OS regardless of first- or second-line treatment use.

Conclusions:

• Administering targeted therapy first in ALK-positive NSCLC patients significantly enhances progression-free survival.
• The sequence of targeted therapy and chemotherapy does not lead to a statistically significant difference in overall survival.
• Findings suggest prioritizing targeted therapy for improved PFS in this patient population.